Peer-reviewed veterinary case report
Survivin blocker EZN-3042 slows canine lymphoma and bone cancer cells
By Shoeneman, J K et al.·Published in Veterinary and comparative oncology·2016·College of Veterinary Medicine and Biomedical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Survivin inhibition via EZN-3042 in canine lymphoma and osteosarcoma.
- Species:
- dog
Plain-English summary
A study looked at how a new treatment called EZN-3042 could help dogs with lymphoma and osteosarcoma, two types of cancer that are often hard to treat. The researchers found that EZN-3042 works by lowering levels of a protein called survivin, which helps cancer cells survive and grow. In lab tests, this treatment not only slowed down cancer cell growth but also made them more sensitive to other chemotherapy drugs. The results suggest that EZN-3042 could be a promising option for dogs battling these cancers, and further testing in dogs with lymphoma and osteosarcoma is recommended.
People also search for: dog lymphoma treatment · osteosarcoma in dogs · EZN-3042 for canine cancer · dog cancer survival rates · chemotherapy for dogs with cancer
Abstract
Canine lymphoma (LSA) and osteosarcoma (OS) have high mortality rates and remain in need of more effective therapeutic approaches. Survivin, an inhibitor of apoptosis (IAP) family member protein that inhibits apoptosis and drives cell proliferation, is commonly elevated in human and canine cancer. Survivin expression is a negative prognostic factor in dogs with LSA and OS, and canine LSA and OS cell lines express high levels of survivin. In this study, we demonstrate that survivin downregulation in canine LSA and OS cells using a clinically applicable locked nucleic acid antisense oligonucleotide (EZN-3042, Enzon Pharmaceuticals, Piscataway Township, NJ, USA) inhibits growth, induces apoptosis and enhances chemosensitivity in vitro, and inhibits survivin transcription and protein production in orthotopic canine OS xenografts. Our findings strongly suggest that survivin-directed therapies might be effective in treatment of canine LSA and OS and support evaluation of EZN-3042 in dogs with cancer.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24923332/